Literature DB >> 30980197

Rivaroxaban in cervical and "cervico-cerebral" artery dissections: a new therapeutic option?

Giovanni Malferrari1, Domenico Laterza2, Franco Valzania1, Daniela Monaco3, Mauro Silingardi4, Attilia Maria Pizzini4.   

Abstract

Antiplatelet agents and vitamin K antagonists (VKA) are usually used in the treatment of cervical (carotid or vertebral) artery dissections (CADs); however, data about the use of direct oral anticoagulants (DOACs) in these conditions are very limited. DOACs have proven to be effective in stroke reduction in non-valvular atrial fibrillation and, when possible, they are preferred to warfarin because of their better safety profile. We describe four cases of CADs and, firstly in literature, cervico-cerebral (CCADs) in young patients (average age of 42 years) treated with rivaroxaban 20 mg daily. Three of these four dissections had affected the vertebral artery (condition with an unfavorable prognosis and more often complicated by subarachnoid hemorrhages), and the other one was a carotid dissection at the extra-intracranial passage. All patients were followed clinically and with serial neurosonological examinations at 1, 3, and 6 months and with magnetic resonance angiography (MRA) at 6 months. All patients presented a good outcome with vascular recanalization without stroke recurrence or bleedings, even in patients with intracranial vertebral artery involvement. DOACs could be an alternative in young patients with CADs and their use could be considered in intracranial artery dissections too.

Entities:  

Keywords:  Cervical and cervico-cerebral artery dissections; DOACs; Neurosonology; Rivaroxaban; Stroke; Transcranial color Doppler

Mesh:

Substances:

Year:  2019        PMID: 30980197     DOI: 10.1007/s10072-019-03882-8

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  1 in total

1.  Antiplatelet vs. Anticoagulation in Cervical Artery Dissection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Sihua Liu; Xiao Zhang; Xuesong Bai; Yutong Yang; Tao Wang; Xin Xu; Ran Xu; Long Li; Yao Feng; Kun Yang; Xue Wang; Xiaofan Guo; Jing Chen; Yan Ma; Liqun Jiao
Journal:  Front Neurol       Date:  2021-11-24       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.